## RECEIVED

## I. AMENDMENT

JUN 2 4 2003

## In the Claims:

TECH CENTER 1600/2900

Please cancel claims 30-36 without prejudice or disclaimer.

Please amend claim 28 as follows:



28. (Amended) A method of making an antibody that specifically binds to phosphatidylserine, said method comprising administering to an animal a pharmaceutical composition comprising an immunologically effective amount of a phosphatidylserine/polypeptide conjugate composition.

## Please add the following new claims:

- 37. (New) The method of claim 29, wherein said polypeptide is β<sub>2</sub>-glycoprotein I.
- 38. (New) The method of claim 28, wherein the antibody is linked to a detectable label.
- 39. (New) The method of claim 38, wherein the antibody is linked to a radioactive label, a fluorogenic label, a nuclear magnetic spin resonance label, biotin or an enzyme that generates a detectable product upon contact with a chromogenic substrate.



- 40. (New) The method of claim 38, wherein the antibody is linked to an alkaline phosphatase, hydrogen peroxidase or glucose oxidase enzyme.
- 41. (New) The method of claim 28, wherein the antibody is a monoclonal antibody.
- 42. (New) A method of making an antibody that specifically binds to phosphatidylserine, said method comprising administering to an animal a pharmaceutical composition comprising an immunologically effective amount of a phosphatidylserine/polypeptide conjugate composition, wherein the phosphatidylserine/polypeptide conjugate composition is not a phosphatidylserine/KLH conjugate composition.

- 43. (New) The method of claim 42, wherein the pharmaceutical composition comprises a phosphatidylserine/BSA, phosphatidylserine/BGG, or phosphatidylserine/β<sub>2</sub>-glycoprotein I conjugate.
- 44. (New) The method of claim 43, wherein said polypeptide is  $\beta_2$ -glycoprotein I.
- 45. (New) The method of claim 42, wherein the antibody is linked to a detectable label.
- 46. (New) The method of claim 45, wherein the antibody is linked to a radioactive label, a fluorogenic label, a nuclear magnetic spin resonance label, biotin or an enzyme that generates a detectable product upon contact with a chromogenic substrate.
- 47. (New) The method of claim 45, wherein the antibody is linked to an alkaline phosphatase, hydrogen peroxidase or glucose oxidase enzyme.
- 48. (New) The method of claim 42, wherein the antibody is a monoclonal antibody.
- 49. (New) A method of making a monoclonal antibody that specifically binds to phosphatidylserine, said method comprising administering to an animal a pharmaceutical composition comprising an immunologically effective amount of a phosphatidylserine/polypeptide conjugate composition.
- 50. (New) The method of claim 49, wherein the pharmaceutical composition comprises a phosphatidylserine/BSA, phosphatidylserine/BGG, or phosphatidylserine/ $\beta_2$ -glycoprotein I conjugate.
- 51. (New) The method of claim 50, wherein said polypeptide is  $\beta_2$ -glycoprotein I.
- 52. (New) The method of claim 49, wherein the antibody is linked to a detectable label.